| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2007, p. 1863-1864, Vol. 51, No. 5
0066-4804/07/$08.00+0 doi:10.1128/AAC.01273-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Microbiology, Tumor and Cell Biology (MTC), Clinical Microbiology, Karolinska Institute, Stockholm,1 Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala, Sweden2
Received 11 October 2006/ Returned for modification 21 November 2006/ Accepted 7 February 2007
| ABSTRACT |
|---|
|
|
|---|
| TEXT |
|---|
|
|
|---|
The isolates were identified at the species level according to standard methods (6). Disk diffusion tests for susceptibility were performed according to SRGA methodology using species-specific breakpoints (www.srga.org).
Shotgun cloning was performed by cleaving the extracted DNA of each isolate with one of four different restriction endonucleases, EcoRI, PstI, HindIII, or BamHI (Roche Biochemicals, Mannheim, Germany), and ligating the restriction fragments with plasmid vector pUC18 or pUC19 (Invitrogen AB, Sweden) treated with the same restriction enzyme. Ligations were transformed by heat shock into chemically competent E. coli TOP10 cells, a variant of strain DH10B, according to the kit protocol (Invitrogen AB, Sweden). Transformants were selected on Iso-Sensitest agar medium with 50 mg of trimethoprim/liter and 100 mg of ampicillin/liter, with only 50 mg of trimethoprim/liter, or with only 100 mg of ampicillin/liter and were incubated at 37°C for approximately 40 h.
PCR was used to generate DNA templates of cloned fragments for sequence analysis. PCR screening for the newly identified genes dfrA24 and dfrA26 was also performed with the original clinical sample collection. In all cases, boiled lysates of bacteria were used as the DNA template. The protocol and cycling conditions for the PCR were the same as those in previous studies, and the annealing temperatures ranged from 50 to 55°C (3).
Sequencing reactions were performed with PCR products as templates. Primers used for PCR and sequencing of cloned fragments were two forward and two reverse primers specific for the sequences upstream and downstream of the polylinker of the cloning vector and directed toward the presumed insert. The sequencing was performed using the ABI Prism Big Dye Terminator cycle sequencing ready reaction kit, version 3.1 (Applied Biosystems), according to the protocol used previously (3).
The first trimethoprim-resistant E. coli isolate studied, U21, was resistant to ampicillin, trimethoprim (MIC, >32 mg/liter), cotrimoxazole, chloramphenicol, streptomycin, spectinomycin, norfloxacin, and ciprofloxacin and intermediately susceptible to cefuroxime and amoxicillin-clavulanic acid. U21 was PCR positive for the integron-connected sulfonamide resistance gene sul1, although it was not positive for integrons per se in any of several PCR experiments. A small HindIII fragment of 927 bp was cloned under trimethoprim selection (MIC for clone, >32 mg/liter). Nucleotide sequencing revealed the presence of an open reading frame of 558 bp, which encodes an original dihydrofolate reductase homolog and was named dfrA24. The DfrA24 polypeptide has 185 amino acids (aa), and among products of previous sequenced resistance genes it exhibits the highest sequence identity to the gene products of dfrA8 (40%; 52/129 aa) and dfrA9 (32%; 50/153 aa), neither of which is located in a gene cassette in an integron (5, 8). In comparison with all available sequences, the highest score was seen for the dihydrofolate reductase (36%; 63/175 aa) of Porphyromonas gingivalis (NC002950). We noticed a high amino acid sequence identity (44%; 58/126 aa) with dihydrofolate reductase enzymes in several different species of the genus Brucella. The sequence of the dfrA24 gene and its immediate surroundings did not show features of integron-borne mobile gene cassettes.
The second E. coli isolate studied, U93, was resistant to ampicillin, sulfonamides, amoxicillin-clavulanic acid, and streptomycin in addition to its high-level resistance to trimethoprim (MIC, >32 mg/liter) but was susceptible to all other drugs tested. A 400-bp fragment with HindIII and a 1,100-bp fragment with BamHI were successfully cloned and the sequences analyzed (MICs for clones, >32 mg/liter). The inserts turned out to overlap and encoded another new dfr-resembling sequence. This gene was named dfrA26 and was distantly related to dfrA3 (40% identity; 72/178 aa). The gene product was related to several housekeeping dihydrofolate reductases from a range of organisms such as Brucella suis (AE014291) (44% identity; 75/169 aa) and Bartonella quintana strain Toulouse (BX897700) (48% identity; 79/164 aa). The genetic context of the dfrA26 gene did not indicate any carriage as an integron-borne gene cassette.
However, by contrast to the dfrA24 gene, dfrA26 was found to be associated with common region 1 (CR1), an IS91-related element usually found downstream of the 3' conserved segment region of some class 1 integrons (1, 2, 7, 9. The cloned fragment also included a short segment of a thymidylate synthase gene that was possibly linked to the dihydrofolate reductase gene in the source organism. The insertion site for the dfrA26 downstream CR1 is identical with the breakpoints for several of the genes that have been identified in the same context, as shown in Table 1. A broad range of different resistance genes that are generally not carried as gene cassettes have been described in connection with CR1 in recent years. Examples of genes that are linked with such conserved regions and that also share the 5' breakpoint with dfrA26 are dfrA3b, -9, -10, and -18/19, dfrA20, and dfrA23. Other examples of genes in these constant regions with a capturing function are blaCTX-M-9 (AM040708), blaCMY-11 (AF357599), qnrA (AY259085), qnrA4 (DQ058662), qnrB1 (DQ351241), qnrB2 (AY931017), and catA2 (L06822) (7, 9).
|
Nucleotide sequence accession numbers. EMBL accession numbers for the new sequences described are AJ972619 (dfrA24) and AM403715 (dfrA26).
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Published ahead of print on 16 February 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |